Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
| العنوان: | Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial |
|---|---|
| المؤلفون: | Janet E. Brown, J.M. Russell, Hassan Douis, Adrian Cook, Matthew R. Sydes, David Matheson, Narayanan Srihari, Alex Hoyle, Matthew S. Simms, A. Nikapota, Anjali Zarkar, Christopher D. Brawley, F.C. Ingleby, Noel W. Clarke, J. Calvert, John Wagstaff, Duncan C. Gilbert, Gerhardt Attard, Jacob Tanguay, A.W.S. Ritchie, Adnan Ali, Ruth E Langley, Andrew Protheroe, Aurelius Omlin, H. Rush, Anna Lydon, David P. Dearnaley, Malcolm David Mason, James D. Wylie, Silke Gillessen, Simon Chowdhury, L. Capaldi, Sharon Beesley, Joe M O'Sullivan, Mona Parmar, Omi Parikh, Joanna Gale, Jan Wallace, S. Rudman, Chris Parker, Alison Birtle, Archie Macnair, Claire Amos, Stephanie Gibbs, Robin Millman, Robert Jones, Zafar Malik, William Cross, Nicholas D. James, Shaun Tolan |
| المصدر: | STAMPEDE Investigators 2019, ' Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial ', Annals of Oncology . https://doi.org/10.1093/annonc/mdz396 Annals of Oncology |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Androgen deprivation therapy, 03 medical and health sciences, Prostate cancer, STAMPEDE trial, 0302 clinical medicine, Urogenital Tumors, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, hormone naive, medicine, Humans, docetaxel, Progression-free survival, Neoplasm Metastasis, Disease burden, Aged, Proportional Hazards Models, Retrospective Studies, Manchester Cancer Research Centre, business.industry, Proportional hazards model, ResearchInstitutes_Networks_Beacons/mcrc, Prostatic Neoplasms, Androgen Antagonists, Retrospective cohort study, Hematology, Original Articles, Middle Aged, medicine.disease, prostate cancer, Progression-Free Survival, metastatic, 030104 developmental biology, Docetaxel, randomised control trial, 030220 oncology & carcinogenesis, Disease Progression, Hormonal therapy, business, medicine.drug |
| الوصف: | Background\ud \ud STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcomes stratified by metastatic burden for M1 patients.\ud \ud \ud \ud Methods\ud \ud We randomly allocated patients in 2 : 1 ratio to standard-of-care (SOC; control group) or SOC + docetaxel. Metastatic disease burden was categorised using retrospectively-collected baseline staging scans where available. Analysis used Cox regression models, adjusted for stratification factors, with emphasis on restricted mean survival time where hazards were non-proportional.\ud \ud \ud \ud Results\ud \ud Between 05 October 2005 and 31 March 2013, 1086 M1 patients were randomised to receive SOC (n = 724) or SOC + docetaxel (n = 362). Metastatic burden was assessable for 830/1086 (76%) patients; 362 (44%) had low and 468 (56%) high metastatic burden. Median follow-up was 78.2 months. There were 494 deaths on SOC (41% more than the previous report). There was good evidence of benefit of docetaxel over SOC on OS (HR = 0.81, 95% CI 0.69–0.95, P = 0.009) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P = 0.827). Analysis of other outcomes found evidence of benefit for docetaxel over SOC in failure-free survival (HR = 0.66, 95% CI 0.57–0.76, P 0.5 in each case). There was no evidence that docetaxel resulted in late toxicity compared with SOC: after 1 year, G3-5 toxicity was reported for 28% SOC and 27% docetaxel (in patients still on follow-up at 1 year without prior progression).\ud \ud \ud \ud Conclusions\ud \ud The clinically significant benefit in survival for upfront docetaxel persists at longer follow-up, with no evidence that benefit differed by metastatic burden. We advocate that upfront docetaxel is considered for metastatic hormone naïve prostate cancer patients regardless of metastatic burden. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0923-7534 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae50219cab2735395675e6bd870c6e64 https://doi.org/10.1093/annonc/mdz396 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....ae50219cab2735395675e6bd870c6e64 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 09237534 |
|---|